<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114198">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01763567</url>
  </required_header>
  <id_info>
    <org_study_id>CEP244</org_study_id>
    <nct_id>NCT01763567</nct_id>
  </id_info>
  <brief_title>Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)</brief_title>
  <acronym>MAHI</acronym>
  <official_title>A Multi-Phased, Multi-Center Study to Evaluate Safety and Device Performance of the Medtronic Hospital Glucose Management System (HGMS) in Critically Ill Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and device performance of the Medtronic
      Hospital Glucose Management System (HGMS) for up to 72-hours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Moderate and severe anticipated device and procedure related adverse events
All serious adverse events and unanticipated adverse device effects related events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Performance</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functionality of HGMS
Accuracy
Alarms Specificity and Sensitivity (providing there are sufficient points)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Transient or Diabetes-related Hyperglycemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients admitted to the Intensive Care Unit (ICU) and on intravenous (IV) insulin
        therapy for the treatment of transient or diabetes-related hyperglycemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is at least 18 years old

          2. Subject is admitted to the ICU

          3. Subject has a treatment regimen that includes a glucose target range of â‰¥140 mg/dl

          4. Subject has a treatment regimen that includes an intended continuous intravenous
             insulin for at least 24 hours

             a. Including patients with no previous diagnosis of Diabetes Mellitus

          5. Subject has anticipated life expectancy greater than 96 hours

          6. Subject has recent platelet count greater than 30,000 per micro-liter

        Exclusion Criteria:

          1. Subject currently has a suspected or diagnosed medical condition that, in the opinion
             of the Investigator, warrants exclusion from the study or prevents the subject from
             completing the study

          2. Subject is currently participating in another investigational drug or device study

          3. Subject is pregnant, as determined by hospital admission

          4. Subject is receiving treatment that includes Hydroxyurea.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Kosiborod, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Luke's Hospital Mid America Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Luke's Hospital Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 4, 2013</lastchanged_date>
  <firstreceived_date>December 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medtronic</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Hospital</keyword>
  <keyword>Continuous Glucose Monitor</keyword>
  <keyword>Intensive Care Unit</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
